Previous 10 | Next 10 |
BEPro is a novel prodrug technology to enhance oral delivery of active nucleotides Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive ...
Ligand has a cornucopia of productive assets. Ligand has one cash cow, Captisol, that has been generating outsized revenues. Gilead is an important Captisol customer using Captisol in its remdesivir, an asset with an uncertain future. Shareholders can take heart that Liga...
A list of 62 recent IPOs debuted on The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 reconstitution. Following up on our previous article on recently-IPOd biotech stocks joining the index, in this article, we discuss another four biotechs ma...
Digital Turbine (NASDAQ: APPS) , the leading independent mobile growth platform that supercharges advertising and monetization, was featured in this week’s Simply Wall St Journal. The piece, which also discusses The Kroger Company (NYSE: KR) and Walmart Inc. (NYSE: WMT) , offers...
Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600 Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Joi...
First regulatory approval of an OmniAb-derived antibody Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimber...
Sparsentan treatment demonstrated a statistically significant mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator irbesartan (p<0.0001) Sparsentan has been generally well-tolerated and consistent with the previo...
COLUMBUS, Ohio, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it has completed enrollment in its Phase 2 r...
Image source: The Motley Fool. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Q2 2021 Earnings Call Jul 29, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earn...
Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Conference Call July 29, 2021 04:30 PM ET Company Participants Simon Latimer - Head of IR John Higgins - CEO Matthew Korenberg - CFO Matt Foehr - COO Matthew Foehr - Conference Call Participants Lawrence Solow - CJS Securities Matt H...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...